- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07951099
Quality Of Life in Prostate Cancer Patients Initiating Triptorelin (QOCPIT)
QOCPIT (Quality Of Life in Prostate Cancer Patients Initiating Triptorelin): A Prospective Observational Study to Evaluate Baseline Factors That Stabilize or Improve Health-related Quality of Life.
Prostate cancer and its treatment, particularly androgen deprivation therapy (ADT) may affect different aspects of a person's quality of life, including physical well-being and daily activities.
The purpose of this study is to evaluate baseline factors that stabilize or improve quality of life in patients with prostate cancer who are initiating triptorelin treatment as ADT, in routine clinical practice.
Participants in this study will be patients with prostate cancer whose treating physician has decided to initiate treatment with triptorelin.
This is an observational study. No treatment will be assigned as part of the study, and all medical decisions will be made by the treating physician according to routine clinical practice.
Participants will be followed for approximately 6 months. Information collected during the study may include demographics and medical characteristics, prostate cancer and treatments characteristics, physical activity, supportive care and quality of life. Questionnaires about quality of life and physical activity will be completed by participants at the start of the study and again approximately 6 months later. Information on adverse events occurring during the study will also be collected.
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studiekontakt
- Namn: Ipsen Clinical Study Enquiries
- Telefonnummer: See email
- E-post: clinical.trials@ipsen.com
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Adult males with prostate cancer initiating triptorelin treatment in routine clinical practice and meeting the study eligibility criteria.
Beskrivning
Inclusion Criteria:
Patients are eligible to be included in the study only if all the following criteria apply:
- Males ≥18 years old.
- Patient with histologically confirmed PCa.
- Patient eligible to start triptorelin in its labelled indication for at least 6 months and for whom the decision to start triptorelin was made voluntarily by the physician as part of routine medical practice, prior to the inclusion in the study.
- Patient able to understand and complete study-related questionnaires.
- Patient having been informed and not opposed to participating in the study.
- Patient covered by healthcare insurance.
Exclusion Criteria
Patients will not be included in the study if they meet any of the following criteria:
- Patient currently participating in any interventional clinical trial.
- Patient who received a hormonal treatment during the last 6 months before inclusion (or hormonal treatment whose duration of action may impact the 6 months before inclusion).
- Patient under tutorship or curatorship; patients under safeguard of justice or deprived of his liberty by an administrative or court decision.
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: PROSPECTIVE
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Identification of baseline factors including: demographic, clinical, disease and treatment factors, associated with stabilization (change:]-10; 10[) or improvement (change ≥10) of Functional Assessment of Cancer Therapy-Prostate (FACT-P) total score
Tidsram: At 6 months
|
At 6 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Participants' baseline demographic characteristics
Tidsram: At baseline
|
Including:
|
At baseline
|
|
Participants' clinical characteristics at baseline
Tidsram: At baseline
|
Including:
|
At baseline
|
|
Prostate cancer characteristics at diagnosis and baseline
Tidsram: At baseline
|
Including:
|
At baseline
|
|
Participants symptoms at baseline
Tidsram: At baseline
|
At baseline
|
|
|
Participants' PCa treatment patterns at baseline
Tidsram: At baseline
|
|
At baseline
|
|
Participants' healthcare pathway/supportive care done or planned
Tidsram: At baseline
|
Including:
|
At baseline
|
|
Evolution of PCa at 6-month follow-up according to investigator's opinion
Tidsram: At 6 months
|
Evolution of PCa at 6-month follow-up according to investigator's opinion: control / stable / progression. |
At 6 months
|
|
Symptoms and biological characteristics at 6 months
Tidsram: At 6 months
|
At 6 months
|
|
|
Participant's level of physical activity, using International Physical Activity Questionnaire (IPAQ) questionnaire
Tidsram: At 6 months
|
The International Physical Activity Questionnaire (IPAQ) is a participant-reported questionnaire used to assess physical activity level. Higher scores indicate higher levels of physical activity. |
At 6 months
|
|
Participants' Quality Of life (QoL)
Tidsram: At baseline and at 6 months
|
|
At baseline and at 6 months
|
|
Participants' PCa treatment patterns at 6 months
Tidsram: At baseline and at 6 months
|
|
At baseline and at 6 months
|
|
Participants' healthcare pathway/supportive care at 6 months
Tidsram: At 6 months
|
• Participant's healthcare pathway/type of supportive care in case of changes. |
At 6 months
|
|
Identification of factors associated with participant's quality of life
Tidsram: At 6 months
|
• Identification of baseline factors, including demographic, clinical, disease and treatment factors, associated with stabilization (change: ]-3;3[) or improvement (change ≥3) of Physical Well-Being (PWB) and Prostate Cancer Specific (PCS) sub-scores of FACT-P at 6 months after inclusion, using a logistic model. |
At 6 months
|
|
Percentage of participants with adverse events
Tidsram: From enrollment to Month 6
|
An adverse event (AE) is any untoward medical occurrence in a participant. The percentage of participants experiencing at least one adverse event, including cardiovascular events occurring after initiation of triptorelin treatment, will be assessed during study follow-up. |
From enrollment to Month 6
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Ipsen Medical Director, Ipsen
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CLIN-52014-030
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.
Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
Tidsram för IPD-delning
Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.
Kriterier för IPD Sharing Access
Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .